About Mikael Dolsten
Mikael Dolsten, MD, PhD, joined Typewriter's board as an independent director when the company came out of stealth in September 2026. He was chief scientific officer and president of worldwide R&D at Pfizer, where he led the discovery and development of more than 35 approved medicines and vaccines.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Mikael Dolsten in the role, so the role may have started earlier or lasted longer.
Typewriter Therapeutics, Inc. Current
Independent Board Director
2026 – Present · Cambridge, MA
Typewriter Therapeutics develops all-RNA medicines that insert a full working gene at a natural safe harbor site in the genome, starting with in vivo CAR-T.
BE
BenchSci Current
Board Chair
OM
Orbis Medicines Current
Board Chair
MS
Mast Cell Sciences Current
Board Chair
QT
Quarry Thera Current
Board Chair
FB
Formation Bio Current
Chair of the R&D Investment Committee
BS
Blackstone Life Sciences Current
Senior Advisor
AP
ARCH Venture Partners Current
Senior Advisor
CP
Canaan Partners Current
Senior Advisor
GV
GV (Google Ventures) Current
Senior Advisor
BC
Bain & Company Current
Senior Advisor
LU
Lund University Current
Adjunct Professor
PF
Pfizer
Chief Scientific Officer and President, Worldwide Research & Development
AS
AstraZeneca
BI
Boehringer Ingelheim
PH
Pharmacia
WP
Wyeth Pharmaceuticals
AT
Agilent Technologies
Board member
SO
SOBI
Board member
CD
ChAI Discovery
Board member
FB
FairJourney Biologics
Board member
IM
Immunai
Board member
AB
Arbor Biotechnologies
Board member
EB
Enveda Biosciences
Board member
Education
- MD, Lund University
- PhD, Tumor Immunology, Lund University
Key Colleagues at Startups
The people Mikael Dolsten works with at each company, as listed on that company's latest Form D.
Typewriter Therapeutics, Inc. · Form D, Sep 21, 2026
LT
Laura Tadvalkar
Director
MS
Matthew Stanton
Chief Executive Officer and Board Director
KH
Kenneth Horne
Director